Compare NAT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAT | GERN |
|---|---|---|
| Founded | 1995 | 1990 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.1M | 753.3M |
| IPO Year | 1997 | 1996 |
| Metric | NAT | GERN |
|---|---|---|
| Price | $3.38 | $1.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $3.25 | $3.00 |
| AVG Volume (30 Days) | 2.9M | ★ 7.1M |
| Earning Date | 11-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 10.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $294,820,000.00 | $183,403,000.00 |
| Revenue This Year | N/A | $147.34 |
| Revenue Next Year | $32.00 | $39.11 |
| P/E Ratio | $374.40 | ★ N/A |
| Revenue Growth | N/A | ★ 522.13 |
| 52 Week Low | $2.13 | $1.04 |
| 52 Week High | $3.93 | $3.80 |
| Indicator | NAT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 55.61 |
| Support Level | $3.34 | $1.30 |
| Resistance Level | $3.78 | $1.45 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 7.96 | 53.70 |
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.